Lakewood-Amedex highlights Nasdaq debut and Nu-3 push

Lakewood-Amedex Biotherapeutics said its second quarter brought a Nasdaq listing, a stronger balance sheet and continued progress on Nu-3, its lead treatment for infected diabetic foot ulcers. The company is now preparing for a Phase 2a trial that could help validate both the drug candidate and its broader antimicrobial platform.

Why it matters: - Lakewood-Amedex is trying to turn Nu-3 into a clinical proof point for its Bisphosphocin® platform. - The company also wants a stronger balance sheet and Nasdaq visibility to support development and future financing. - Infected diabetic foot ulcers remain a serious infection with limited treatment options, especially as antimicrobial resistance grows.

What happened: - Chief Executive Officer Kelvin Cooper, Ph.D., issued a shareholder letter outlining the company's clinical, corporate and financial progress. - Lakewood-Amedex successfully listed on the Nasdaq Capital Market under the ticker symbol LABT on April 23, 2026. - The company said it is preparing to initiate a Phase 2a trial of Nu-3, a topical gel candidate for infected diabetic foot ulcers. - The shareholder letter was released on September 21, 2026.

The details: - Lakewood-Amedex said it completed a private placement of Series C Convertible Preferred Stock before the Nasdaq listing and raised about $7.5 million in gross proceeds. - The Nasdaq listing triggered automatic conversion of outstanding preferred stock and convertible notes into common stock. - Lakewood-Amedex said the transactions improved liquidity, reduced current liabilities and simplified its capital structure. - The company said existing cash resources are sufficient to support currently planned operating activities. - Nu-3 showed positive preclinical safety and tolerability results, including low systemic exposure after topical administration and no interference with natural wound healing. - Those findings supported selection of 2%, 5% and 10% dose strengths for the Phase 2a trial. - Nu-3 has also shown rapid, broad-spectrum bactericidal activity against multidrug-resistant pathogens. - David G. Armstrong, DPM, MD, Ph.D., is serving as Study Chair and Scientific Advisor. - Professional Education and Research Institute, led by Charles M. Zelen, DPM, is running the study. - Lakewood-Amedex said its global intellectual property portfolio now includes 72 granted patents and 29 pending patent applications. - At the annual meeting on September 22, shareholders are being asked to approve an increase in authorized common shares from 12.5 million to 100 million. - Shareholders are also being asked to authorize a reverse split of up to 1-for-20, if needed to maintain the Nasdaq listing. - The company said there is no current plan to use reverse-split authority unless the stock price requires it to preserve the listing. - A registration statement filed on September 18 covers remaining preferred shares that can still convert into common stock. - The preferred shareholder cannot own more than 4.99% of common stock at any time, so conversions and sales occur in stages. - Lakewood-Amedex said it will have no preferred stock outstanding and no preferred dividend after the final preferred share converts.

Between the lines: - The Nasdaq listing gives Lakewood-Amedex a more traditional public-market profile at a moment when it is trying to prove a lead asset in the clinic. - The capital-structure cleanup appears designed to reduce financing complexity before Phase 2a data arrive. - If Nu-3 advances, the company could gain evidence not only for infected diabetic foot ulcers but also for a broader antimicrobial strategy. - The shareholder request for more authorized shares and reverse-split flexibility signals that management wants room to protect the listing and raise capital if needed.

What's next: - Lakewood-Amedex plans to initiate the Nu-3 Phase 2a trial and begin generating clinical data in infected diabetic foot ulcers. - The company will continue conversion of the remaining preferred shares in stages. - Management said it will update shareholders when the last preferred share converts. - Investors will also be watching the Sept. 22 annual meeting vote and the company's next clinical update.

The bottom line: - Lakewood-Amedex is positioning Nu-3 as the key catalyst now that the company is public on Nasdaq and better capitalized. - The next major test is whether the Phase 2a trial can validate the drug candidate and the platform behind it.

More information: the company's announcement - For company background, see Lakewood-Amedex's website.